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Summary
Purpose:  Statins  attenuate  angiotensin  II-induced  myocyte  hypertrophy  and  this  might  increase
the cardioprotective  effects  of  renin—angiotensin  system  inhibition  in  the  ischemic  heart.  In
this study,  we  investigated  the  cardioprotective  effects  of  combination  therapy  with  low-dose
simvastatin  and  low-dose  losartan  using  a  rat  myocardial  infarction  model.
Methods: Myocardial  infarction  was  created  in  rats  by  left  anterior  descending  artery  liga-Myocardial  infarction tion, and  the  animals  were  randomly  allocated  to  one  of  four  groups:  control  (n  =  8),  losartan
3 mg/kg/day  (n  =  8),  simvastatin  2  mg/kg/day  (n  =  8),  and  losartan  3  mg/kg/day  plus  simvas-
tatin 2  mg/kg/day  (n  =  8).  Each  treatment  was  started  on  the  day  of  coronary  ligation,  and
hemodynamics,  myocardial  blood  ﬂow,  and  infarct  size  were  measured  after  28  days.
Results:  Blood  pressure,  heart  rate,  and  left  ventricular  systolic  and  end-diastolic  pressures
were not  signiﬁcantly  different  comparing  the  control  group  with  the  3  other  treatment  groups.
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The  peak  positive  ﬁrst  derivative
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Myocardial  blood  ﬂow,  left  ventri
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Conclusions:  Treatment  with  3  mg
or simvastatin  alone  improved  le
model. The  result  suggests  that  s
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lockade  of  the  renin—angiotensin  system  (RAS)  by
ngiotensin-converting  enzyme  inhibitors  (ACEIs)  or
ngiotensin  receptor  blockers  (ARBs)  inhibits  left  ven-
ricular  hypertrophy  and  left  ventricular  remodeling,
meliorates  left  ventricular  dysfunction  [1],  and  conse-
uently  improves  long-term  prognosis  [2]  in  patients  with
schemic  as  well  as  non-ischemic  heart  failure.
The  3-hydroxy-3-methylglutaryl-CoA  (HMG-CoA)  reduc-
ase  inhibitors,  statins,  have  been  shown  to  reduce
ardiovascular  morbidity  and  mortality  due  to  cholesterol-
owering  effects  [3].  However,  other  lipid-independent
leiotropic  actions  may  contribute  to  cardioprotection
nduced  by  statins  [4],  and  this  has  been  documented  in
xperimental  studies  demonstrating  a  decrease  in  oxidative
tress,  inﬂammation,  inhibition  of  thrombogenic  response,
nd  atherosclerotic  plaque  formation  [5]  resulting  in  atten-
ation  of  vascular  endothelial  dysfunction.  The  mechanism
esponsible  for  the  pleiotropic  effects  of  statins  involve  the
nhibition  of  small  GTP-binding  proteins,  such  as  Ras,  Rho,
nd  Rac,  which  modulate  a  wide  variety  of  cellular  process
4]  including  the  myocardial  response  to  ischemic  injury.  We
ypothesized  that  statins  might  have  synergistic  cardiopro-
ective  effects  for  renin—angiotensin  system  inhibition  in
he  ischemic  heart.  Based  on  this  hypothesis,  in  this  study
e  investigated  the  effects  of  combination  therapy  with  a
tatin  (simvastatin)  or  an  ARB  (losartan)  using  a  low-dose  of
oth  agents,  which  might  not  be  effective,  on  cardiac  func-
ion,  coronary  blood  ﬂow,  and  infarct  size  in  a  rat  myocardial
nfarction  model.
ethods
tudy  protocol
he  left  anterior  descending  coronary  artery  was  lig-
ted  2  mm  below  the  left  atrium  with  a  7—0  prolene
uture  in  32  adult  (8-week-old)  male  Sprague-Dawley
ats  (191.9—230.6  g).  Rats  were  randomly  allocated  to
ne  of  4  treatment  groups:  control  (0.5%  CMC-Na+ solu-
ion;  n  =  8),  losartan  3  mg/kg/day  (n  =  8),  simvastatin
 mg/kg/day  (n  =  8),  or  losartan  3  mg/kg/day  plus  simvas-
atin  2  mg/kg/day  (n  =  8).  Doses  for  oral  administration  were
ecided  to  be  10%  of  commonly  used  doses,  30  mg/kg/day
nd  20  mg/kg/day  for  losartan  and  simvastatin  in  the  rat
xperiment,  respectively,  which  yields  plasma  concentra-
ion  similar  to  that  seen  in  patients  taking  clinical  doses.
oth  agents  were  suspended  in  0.5%  CMC-Na+ solution  and
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 of  left  ventricular  pressure  (peak  LV  dP/dt)  was  equivalent
h  the  losartan  and  simvastatin  groups.  However,  the  peak  LV
n  plus  simvastatin  group  than  in  the  control  group  (p  <  0.05).
cular  weight,  and  infarct  size  were  not  signiﬁcantly  altered  by
/kg/day  losartan  plus  2  mg/kg/day  simvastatin  but  not  losartan
ft  ventricular  systolic  function  in  a  rat  myocardial  infarction
tatins  given  in  combination  with  angiotensin  receptor  blockers
ctive  effects,  even  at  low-doses  for  each  agent.
ology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
ere  given  to  rats  by  gastric  gavage  once  a  day.  Each
reatment  was  started  on  the  day  of  onset  of  myocardial
nfarction  by  coronary  ligation.  Hemodynamic  measure-
ents  were  performed  28  days  after  the  onset  of  myocardial
nfarction  under  barbiturate  anesthesia  and  controlled  ven-
ilation.  After  the  measurements,  the  anesthetized  rats
ere  euthanized  with  a  lethal  dose  of  barbiturate,  and  the
earts  were  removed  to  measure  myocardial  blood  ﬂow  and
nfarct  size.
emodynamic  measurement
nder  barbiturate  anesthesia  and  controlled  ventilation,  a
atheter  was  inserted  into  the  right  carotid  artery  to  mea-
ure  systolic  (SBP)  and  diastolic  blood  pressure  (DBP)  and
eart  rate  (HR).  Then,  the  catheter  tip  was  advanced  into
he  left  ventricle  to  record  left  ventricular  systolic  (LVSP)
nd  end-diastolic  pressures  (LVEDP).  Finally,  left  ventricu-
ar  pressure  was  differentiated  and  the  peak  positive  ﬁrst
erivative  of  left  ventricular  pressure  (peak  LV  dP/dt)  was
easured.
yocardial  blood  ﬂow  measurement
n  4  rats  from  each  group,  myocardial  blood  ﬂow  was  mea-
ured  using  ﬂuorescent  microspheres.  The  microspheres
ere  injected  into  the  left  ventricle  through  the  catheter.
nother  catheter  was  inserted  into  the  abdominal  aorta  via
he  femoral  artery  and  a  reference  blood  sample  was  with-
rawn  at  a  rate  of  0.84  mL/min.  After  euthanasia,  the  left
entricle  was  removed  and  weighed.  The  left  ventricular  tis-
ue  was  digested  with  4  M  potassium  hydroxide  containing  2%
ween  80.  Then,  the  microspheres  were  ﬁltered  and  dried,
nd  dimethyl  formamide  was  added  to  extract  the  dye  in
he  solution.  The  solution  was  centrifuged  at  4700  rpm  for
 min.  Finally,  the  supernatant  was  collected  to  measure  the
bsorbance  and  the  optical  density  (OD)  was  calculated.  The
eference  blood  sample  was  similarly  treated  and  myocar-
ial  blood  ﬂow  was  calculated  using  a  standard  formula
tissue  OD  ×  reference  blood  withdrawal  rate/tissue  weight
g)  ×  reference  blood  OD].
etermination  of  infarct  size
n  4  rats  of  each  group,  the  infarct  size  was  determined.
fter  euthanasia,  the  whole  heart  was  excised  and  the
ight  and  left  ventricles  were  dissected.  The  weights  of
he  whole  heart,  the  right  ventricle  and  the  left  ventricle
ere  measured.  Then,  the  left  ventricle  was  sliced  into  5
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Table  1  Global  parameters  at  the  28th  day  in  each  treatment  group.
Control  (n  =  8)  Losartan  (n  =  8)  Simvastatin  (n  =  8)  Losartan  +  Simvastatin  (n  =  8)
SBP  (mmHg)  125  ±  7  127  ±  4  126  ±  5  141  ±  7
DBP (mmHg)  104  ±  5  105  ±  3  101  ±  3  112  ±  5
HR (/min)  403  ±  15  441  ±  6  406  ±  12  435  ±  16
LVSP (mmHg)  126  ±  5  129  ±  4  128  ±  6  126  ±  5
LVEDP (mmHg) 10.0  ±  1.1  6.8  ±  1.2  10.2  ±  2.5  6.9  ±  0.6
Peak LV  dP/dt  (mmHg/sec) 7229 ±  408  8263 ±  395  7375 ±  646  9071  ±  528*
Whole  heart  weight  (g) 1.280 ±  0.036  1.322 ±  0.053  1.343 ±  0.066  1.281 ±  0.047
Ventricular weight  (g) 1.122 ±  0.023  1.146 ±  0.036  1.155 ±  0.036  1.114 ±  0.030
Left ventricular  weight  (g)  0.798  ±  0.019  0.816  ±  0.016  0.806  ±  0.015  0.765  ±  0.021
Myocardial blood  ﬂow  (mL/min/g)  3.87  ±  0.89  (n  =  4)  3.96  ±  0.54  (n  =  4)  3.79  ±  0.47  (n  =  4)  3.83  ±  0.73  (n  =  4)
Infarct size  (%)  29.0  ±  1.6  (n  =  4)  29.8  ±  2.9  (n  =  4)  26.7  ±  3.5  (n  =  4)  27.4  ±  2.8  (n  =  4)
SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; LVSP, left ventricular systolic pressure; LVEDP, left ventricular
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*p < 0.05 vs control.
transverse  sections.  After  weighing  each  slice,  4  of  the  5
sections  were  stained  with  1%  triphenyl  tetrazolium  chloride
(TTC)  in  a  phosphate  buffer  to  detect  infarcted  tissue.  The
infarct  area  and  left  ventricular  area  were  measured  using
speciﬁc  image  analysis  software  (WinROOF  ver.  3.1;  Mitani,
Tokyo,  Japan).  The  weight  of  the  infarcted  tissue  in  each
section  was  calculated  as  the  infarct  area/left  ventricular
area  ×  section  weight.  Infarct  size  (%)  was  calculated  as  the
weight  of  all  infarcted  tissue/left  ventricular  weight.
Statistical  analysisData  are  expressed  as  the  mean  ±  SE.  Normality  of  the  distri-
bution  of  variables  was  assessed  using  a  Bartlett  test.  If  the
data  were  normally  distributed,  comparisons  of  each  treat-
ment  group  with  the  control  group  were  performed  using
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Figure  1  Peak  positive  ﬁrst  derivative  of  left  ventricular  pressure
peak LV  dP/dt  was  similar  in  the  groups  of  losartan  alone  and  simvas
plus simvastatin  group,  compared  to  the  control  group.he  parametric  Dunnett  test.  If  the  data  were  not  normally
istributed,  the  groups  were  compared  using  a  nonparamet-
ic  Dunnett  test.  A  value  of  p  <  0.05  was  considered  to  be
tatistically  signiﬁcant.
esults
ll  of  the  rats  survived  for  28  days  after  the  onset  of  myocar-
ial  infarction.  Global  parameters  measured  on  the  28th  day
f  each  treatment  are  shown  in  Table  1  and  Fig.  1.  Compared
o  control  group  treated  with  0.5%  CMC-Na+ solution,  SBP,
BP,  HR,  LVSP,  and  LVEDP  were  not  signiﬁcantly  different  in
he  groups  treated  with  losartan  alone,  simvastatin  alone,
nd  losartan  plus  simvastatin  (Table  1).  The  peak  LV  dP/dt
as  equivalent  between  the  control  group  and  the  groups
reated  with  losartan  alone  and  simvastatin  alone.  However,
.05
Si t ti Losartanmvas a n
(n=8) +Simvastatin
(n=8)
 (peak  LV  dP/dt)  at  the  28th  day  in  each  treatment  group.  The
tatin  alone  to  the  control  group  but  was  greater  in  the  losartan
94  R.  Sohma  et  al.
Figure  2  Infarct  area  in  the  sliced  section  at  papillary  muscle  level.  Infarct  size  was  equivalent  in  each  group  of  losartan  alone
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iB), simvastatin  alone  (C)  and  losartan  plus  simvastatin  (D)  to  t
he  peak  LV  dP/dt  was  signiﬁcantly  greater  in  the  losartan
lus  simvastatin  group  than  in  the  control  group  (9071  ±  528
s  7229  ±  408  mmHg/s,  p  <  0.05)  (Fig.  1).  Myocardial  blood
ow  was  equivalent  comparing  the  control  group  with  the
roups  treated  with  losartan  alone,  simvastatin  alone,  or
osartan  plus  simvastatin.  Furthermore,  the  whole  heart
eight,  ventricular  weight,  left  ventricular  weight,  and
nfarct  size  (%)  were  also  equivalent  comparing  the  control
roup  with  the  groups  treated  with  losartan  alone,  simvas-
atin  alone,  or  losartan  plus  simvastatin  (Table  1  and  Fig.  2).
iscussion
he  major  ﬁnding  of  our  study  is  that  treatment  with  losar-
an  3  mg/kg/day  plus  simvastatin  2  mg/kg/day  for  28  days
howed  an  improvement  in  peak  LV  dP/dt  in  a  rat  myocar-
ial  infarction  model,  although  each  monotherapy  did  not
how  such  an  effect.  Doses  of  losartan  and  simvastatin  were
0%  of  commonly  used  doses  in  the  rat  model,  30  mg/kg/day
nd  20  mg/kg/day,  respectively,  which  yields  plasma  con-
entration  corresponding  to  clinical  doses.  These  results
uggest  that  low-dose  statins  might  have  cardioprotective
ffects  when  given  in  combination  with  low-dose  ARBs  in
he  ischemic  heart.
It  has  been  postulated  that  inhibition  of  the  renin-
ngiotensin  system  produces  beneﬁcial  effects  on  cardiac
unction  in  ischemic  as  well  as  non-ischemic  heart  failure.
CEIs,  ARBs,  or  both  have  been  demonstrated  to  increase
oronary  blood  ﬂow  and  to  reduce  infarct  size  in  canine
yocardial  ischemia  models  via  a  bradykinin-dependent
t
n
l
pntrol  group  (A).
echanism  [6].  Myocardial  ﬁbrosis  is  a  major  feature  of  left
entricular  remodeling  after  myocardial  infarction,  which  is
ainly  driven  by  angiotensin  II  [7,8]. In  fact,  ACEIs  and  ARBs
ave  been  shown  to  inhibit  cardiac  remodeling  [8].  Further-
ore,  it  has  recently  been  demonstrated  that  statins  also
ave  cardioprotective  as  well  as  vascular  protective  effects
hat  are  independent  of  their  lipid-lowering  activity  [9].
cute  and  chronic  statin  treatment  improves  post-ischemic
eft  ventricular  contractile  dysfunction  in  the  isolated  rat
eart  [10]. Statins  also  reduce  infarct  size  in  acute  myocar-
ial  infarction  or  in  an  ischemia/reperfusion  model  [11].
ao  et  al.  demonstrated  that  the  infarct  size  reduction  by
tatins  resulted  from  the  pleiotropic  effect  represented  by
ncreased  nitric  oxide  production  [12]. Activation  of  phos-
hatidylinositol  3 kinase  (PI3K)/Akt  by  statins  may  exert
 preconditioning-like  effect  to  limit  infarct  size  [13]. In
ddition,  statins  may  modulate  left  ventricular  remodel-
ng  through  effects  on  matrix  metalloproteinases  [14,15].
mprovement  of  cardiac  function  by  short-term  statin  ther-
py  has  also  been  documented  in  the  clinical  setting  [16,17].
Combined  effects  of  statins  and  ARBs  on  cardiovascular
ystems  have  been  previously  reported.  Lee  et  al.  demon-
trated  additive  effects  of  pravastatin  and  olmesartan  on
educed  left  ventricular  remodeling  in  rat  myocardial  infarc-
ion  model  [18]. Yamamoto  et  al.  reported  that  pravastatin
nhanced  beneﬁcial  effects  of  olmesartan  on  vascular  injury
n  salt-sensitive  hypertensive  rats  [19]. In  the  present  study,
he  low-dose  treatment  with  losartan  plus  simvastatin  did
ot  alter  SBP,  DBP,  LVSP,  LVEDP,  myocardial  blood  ﬂow,
eft  ventricular  weight,  and  infarct  size  (%),  but  increased
eak  positive  LV  dP/dt.  Therefore,  the  improvement  in  left
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[Effect  of  statin  on  myocardial  infarction  
ventricular  systolic  function  by  losartan  plus  simvastatin
might  be  independent  of  preload  and  afterload  reduc-
tion,  infarct  size  reduction,  or  inhibition  of  left  ventricular
remodeling,  although  peak  positive  LV  dP/dt  depends  some-
what  on  preload  and  afterload.  In  our  rat  myocardial
infarction  model,  3  mg/kg/day  losartan  plus  2  mg/kg/day
simvastatin  but  not  the  same  dose  of  losartan  or  simvas-
tatin  alone  improved  left  ventricular  function.  The  result
suggests  that  the  doses  of  each  agent  might  not  solely  inﬂu-
ence  hemodynamics  but  that  the  combination  of  ARBs  and
statins  might  have  synergistic  cardioprotective  effects  in
myocardial  ischemia,  even  at  low-doses  for  both  agents.
Since  statins  have  been  shown  to  attenuate  angiotensin
II-induced  myocyte  hypertrophy  in  cultured  neonatal  rat  car-
diomyocytes  in  a  manner  that  is  probably  mediated  by  the
attenuation  of  oxidative  stress  [6],  we  can  envision  from
our  study  that  the  pleiotropic,  antioxidative  effect  of  statins
may  potentiate  the  cardioprotective  action  of  ARBs  in  the
ischemic  failing  heart.
Study  limitations
This  study  has  several  potential  limitations.  First  this  study
did  not  include  sham  operated  control  data.  In  this  study,
myocardial  infarction  induction  was  performed  through  the
left  anterior  descending  artery  ligation  without  following
reperfusion,  because  we  intended  to  exclude  the  impact
of  reperfusion  injury.  In  most  clinical  settings,  however,
patients  with  acute  myocardial  infarction  receive  emer-
gent  reperfusion  therapy  with  coronary  angioplasty.  So
we  might  have  to  evaluate  the  pharmacological  effects
of  statins  plus  ARBs  on  left  ventricular  function,  using
ischemia/reperfusion  models.  In  addition,  we  did  not  mea-
sure  serum  lipid  levels.  To  establish  that  a  pleiotropic
mechanism  mediates  the  cardioprotective  effects  of  statins
when  given  in  combination  with  ARBs,  we  should  conﬁrm
that  the  cardioprotective  effects  are  independent  of  lipid-
lowering  effects.  In  this  study,  we  used  peak  positive  LV
dP/dt  as  a  marker  of  left  ventricular  systolic  function,  but
did  not  obtain  data  on  peak  negative  LV  dP/dt  (−dP/dt),
which  is  considered  a  marker  of  left  ventricular  diastolic
function.  Since  diastolic  function  has  recently  been  shown
to  be  an  important  determinant  of  long-term  prognosis  in
patients  with  chronic  heart  failure,  the  assessment  of  syner-
gistic  effects  of  ARBs  and  statins  on  diastolic  function  would
be  of  interest.  Finally,  we  did  not  investigate  the  mecha-
nisms  by  which  statins  potentiate  the  effects  of  ARBs.  The
determination  of  the  molecular  basis  of  the  cardioprotec-
tion  will  require  additional  experiments  both  in  vivo  and  in
vitro,  especially  focused  on  antioxidative  effects.
Conclusion
The  present  study  demonstrated  that  treatment  with
3  mg/kg/day  losartan  plus  2  mg/kg/day  simvastatin  but  not
losartan  or  simvastatin  alone  improved  left  ventricular  sys-
tolic  function  in  a  rat  myocardial  infarction  model.  The
result  suggests  that  statins  given  in  combination  with  ARBs
might  have  beneﬁcial  cardioprotective  effects,  even  at  low-
doses  for  each  agent.
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